- Jan 7, 2016
adjunct means along with existing treatment protocols, isn’t it?An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. The drug will help in faster recovery of Covid-19 patients. Twitter/@DRDO_India
The Drugs Controller General of India (DCGI) has granted permission for emergency use of anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s Laboratories (DRL),Hyderabad.
In a release issued on Saturday, the Ministry of Defence said that as per the order, emergency use of this drug as adjunct therapy in moderate to severe COVID-19 patients is permitted. It added that being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country.
|Thread starter||Similar threads||Forum||Replies||Date|
|W||Biocon drug receives DCGI nod for use in moderate to severe COVID-19 patients||Economy & Infrastructure||0|
|V||State Approved terrorism, violence, rape, pedophilia and persecution of minorities||Pakistan||4|
|WHO approves Sinovac COVID-19 vaccine and Covax vaccines roll off Sinopharm factory lines||China||25|
|W||US approves sale of 12 AH-1Z attack helicopters without engines to a unnamed customer||Pakistan||13|